跳至主要内容
临床试验/NCT00002453
NCT00002453已完成不适用

An Open-Label, Multicenter, Compassionate Access Study of the Safety of Tenofovir Disoproxil Fumarate Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients

Gilead Sciences2 个研究点 分布在 1 个国家目标入组 300 人开始时间: 1999年12月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
300
试验地点
2

研究概览

简要总结

This study allows patients who need a new anti-HIV treatment to take tenofovir disoproxil fumarate (tenofovir DF), an experimental drug. This study also looks at any side effects the drug causes.

详细描述

HIV-1-infected patients who are currently receiving stable antiretroviral therapy add tenofovir DF to their regimen. Study participation lasts for approximately 48 weeks. Interested patients should contact their physicians.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Industry

研究点 (2)

Loading locations...

相似试验

A Compassionate Use Study of Tenofovir Disoproxil... | 临床试验